The authors discuss the association between PPARG genetic variants and drug efficacy, as well as the role of alternative splicing and post-translational modifications as contributors to the complexity of PPARγ signaling and to the effects of synthetic PPARγ ligands.
[Current Diabetes Reports]
7753456
{7753456:H2PJC4B8}
apa
50
1
161374
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-62a0aa571b3c989b3ada9d3c4788c455%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22H2PJC4B8%22%2C%22library%22%3A%7B%22id%22%3A7753456%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cataldi%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECataldi%2C%20S.%2C%20Costa%2C%20V.%2C%20Ciccodicola%2C%20A.%2C%20%26amp%3B%20Aprile%2C%20M.%20%282021%29.%20PPAR%26%23x3B3%3B%20and%20Diabetes%3A%20Beyond%20the%20Genome%20and%20Towards%20Personalized%20Medicine.%20%3Ci%3ECurrent%20Diabetes%20Reports%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%286%29%2C%2018.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11892-021-01385-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11892-021-01385-5%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D7753456%26amp%3Bitem_key%3DH2PJC4B8%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PPAR%5Cu03b3%20and%20Diabetes%3A%20Beyond%20the%20Genome%20and%20Towards%20Personalized%20Medicine%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simona%22%2C%22lastName%22%3A%22Cataldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerio%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alfredo%22%2C%22lastName%22%3A%22Ciccodicola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianna%22%2C%22lastName%22%3A%22Aprile%22%7D%5D%2C%22abstractNote%22%3A%22Full%20and%20partial%20synthetic%20agonists%20targeting%20the%20transcription%20factor%20PPAR%5Cu03b3%20are%20contained%20in%20FDA-approved%20insulin-sensitizing%20drugs%20and%20used%20for%20the%20treatment%20of%20metabolic%20syndrome-related%20dysfunctions.%20Here%2C%20we%20discuss%20the%20association%20between%20PPARG%20genetic%20variants%20and%20drug%20efficacy%2C%20as%20well%20as%20the%20role%20of%20alternative%20splicing%20and%20post-translational%20modifications%20as%20contributors%20to%20the%20complexity%20of%20PPAR%5Cu03b3%20signaling%20and%20to%20the%20effects%20of%20synthetic%20PPAR%5Cu03b3%20ligands.%22%2C%22date%22%3A%222021-04-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11892-021-01385-5%22%2C%22ISSN%22%3A%221539-0829%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11892-021-01385-5%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%223XSKJF5U%22%5D%2C%22dateModified%22%3A%222021-04-20T17%3A32%3A21Z%22%7D%7D%5D%7D
Cataldi, S., Costa, V., Ciccodicola, A., & Aprile, M. (2021). PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine. Current Diabetes Reports, 21(6), 18. https://doi.org/10.1007/s11892-021-01385-5 Cite
